The Association for Accessible Medicines has urged US lawmakers to take action on originator tactics used to “game the system”, including ‘product hopping’ and biosimilar patent thickets used to deter competition.
Testifying before a House of Representatives subcommittee on consumer protection and commerce, AAM senior vice-president Jeffrey Francer said that “current...





